Product Details
| Alternative Name: | ABCB1, CD243, P-glycoprotein 1 |
| |
| Clone: | JSB-1 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | MDR (multidrug resistant) Chinese hamster ovary cells (ChrC5). |
| |
| UniProt ID: | P08183 |
| |
| Species reactivity: | Human
Chinese hamster
|
| |
| Specificity: | Recognizes a highly conserved cytoplasmic epitope of the human P-glycoprotein, the expression of which is strongly correlated with the degree of MDR derived MDR cell lines and human MDR cell lines from lung, ovaries and B cell lymphoma. |
| |
| Crossreactivity: | Does not cross-react with mouse, rat or guinea pig P-glycoprotein. |
| |
| Applications: | Flow Cytometry, ICC, IHC (FS), IHC (PS), WB
|
| |
| Recommended Dilutions/Conditions: | Flow Cytometry (at least 1:10)
Immunocytochemistry (acetone-fixed cell preparation at least 1:20)
Immunohistochemistry (acetone-fixed frozen sections at least 1:20, formalin-fixed paraffin sections 1:20)
Western Blot (start optimizing working dilution at 1:10)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Formulation: | Liquid. In PBS containing 0.1% BSA and 0.02% sodium azide. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Figure: Liver cells stained with JSB-1 (ALX-801-004).
Please mouse over
Product Literature References
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study: M. Feldmann, et al.; Lancet Neurol.
12, 777 (2013),
Application(s): IHC using brain tissue,
Abstract;
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma: H.M. Coley, et al.; Eur. J. Cancer
36, 881 (2000),
Abstract;
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma: A.P. Jillella, et al.; Cancer Invest.
18, 609 (2000),
Abstract;
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res.
60, 5269 (2000),
Abstract;
Full Text
Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia: S. Poulain, et al.; Adv. Exp. Med. Biol.
457, 57 (1999),
Abstract;
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia: M.R. Grey, et al.; Leuk. Res.
23, 29 (1999),
Abstract;
Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors: T. Sawada, et al.; Brain Tumor Pathol.
16, 23 (1999),
Abstract;
Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis: G.A. Meijer, et al.; J. Clin. Pathol.
52, 450 (1999),
Abstract;
Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer Res. Clin. Oncol.
125, 117 (1999),
Abstract;
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy: R.E. Jimenez, et al.; Cancer
86, 976 (1999),
Abstract;
Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma: Y.S. Kim, et al.; Clin. Nucl. Med.
24, 874 (1999),
Abstract;
The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein: S. Barg, et al.; PNAS
96, 5539 (1999),
Abstract;
Full Text
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies: F.J. Lacueva, et al.; Histopathology
32, 328 (1998),
Abstract;
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival: A.G. Borg, et al.; Br. J. Haematol.
103, 1083 (1998),
Abstract;
Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42: E. Moran, et al.; Eur. J. Cancer
33, 652 (1997),
Abstract;
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy: S. Chevillard, et al.; Cancer
77, 292 (1996),
Abstract;
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome: N. Baldini, et al.; N. Engl. J. Med.
333, 1380 (1995),
Abstract;
Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase: V.V. Rao, et al.; J. Histochem. Cytochem.
43, 1187 (1995),
Abstract;
Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma: M. Itsubo, et al.; Cancer
73, 298 (1994),
Abstract;
New immunohistochemical "sandwich" staining method for mdr1 P- glycoprotein detection with JSB-1 monoclonal antibody in formalin- fixed, paraffin-embedded human tissues: K. Toth, et al.; Am. J. Pathol.
144, 227 (1994),
Abstract;
Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse: F.A. Sinicrope, et al.; Cancer
74, 2908 (1994),
Abstract;
Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies: J.L. Gala, et al.; J. Clin. Pathol.
47, 619 (1994),
Abstract;
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy: T.M. Grogan, et al.; Blood
81, 490 (1993),
Abstract;
Flow cytometric analysis of P-glycoprotein in normal and leukemic cells: M.I. Tiirikainen, et al.; Ann. Hematol.
65, 124 (1992),
Abstract;
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res.
51, 2628 (1991),
Abstract;
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy: W.S. Dalton, et al.; J. Clin. Oncol.
7, 415 (1989),
Abstract;
Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies: H. Hamada & T. Tsuruo; PNAS
83, 7785 (1986),
Abstract;
